12 June - 13 June 2019

Targeting the Ubiquitin - Proteasome Pathway II

Organised by:

SCI's Fine Chemicals Group

London, UK

Registration opens 12/4/2018

Registration Closed

This event is no longer available for registration.


Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.

The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.


This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.

It is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.

Wednesday 12 June
Welcome and introduction
Latching on to LUBAC: chemical probes for cell biology
David House, Crick-GSK Biomedical LinkLabs
Quantitative, real-time characterization of degradation compounds and their mode of action
Kristin Riching, Promega
Refreshment break, exhibition and poster session
Targeting Deubiquitylases (DUBs): opportunities for collaborative drug discovery
Jason Brown, Ubiquigent
Selective targeting of protein kinase scaffolding and catalytic function
Stefan Knapp, Goethe University Frankfurt
Networking reception
Thursday 13 June
Plate based identification strategies for PROTACs and small molecule degraders
Andreas Hock, AstraZeneca
Small molecule inhibitors of USP7 de-ubiquitylase are superior immune oncology candidates as compared to biologicals
Tauseef Butt, Progenra Inc
Refreshment break, exhibition and poster session
The development of an intracellular degradation probe for pirin protein
Matthew Cheeseman, Institute of Cancer Research
Protacs as biological tools and considerations for oral absorption
Thomas Hayhow, AstraZeneca
Using PROTACs to degrade wild-type and mutant ERα (ESR1) and interrogate benefits of its degradation
Marjoke Froukje Debets, Eli Lilly
Lunch, exhibition and poster session
Keynote: Targeted protein degradation with small molecules: how PROTACs work
Alessio Ciulli, University of Dundee
Refreshment break, exhibition and poster session
Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer
Christiane Kofink, Boehringer Ingelheim
The chemical ligand space of Cereblon – twists and turns on the route to novel small-molecule effectors
Marcus Hartmann, Max Planck Institute for Developmental Biology
Closing remarks

Venue and Contact


14/15 Belgrave Square

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Early bird fees before Friday 3 May 2019
SCI Member
SCI Student Member
SCI Subsidised Member
Standard fees after Friday 3 May 2019
SCI Member
SCI Student Member
SCI Subsidised Member

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

 CPR Accredition Logo



Call for Abstracts

An abstract of maximum one A4 page or 300 words, indicating title, authors and preference for presentation option (15 or 30 minute oral, or poster) should be sent to conferences@soci.org by Friday 12 April 2019 with the subject line "TUPP 2019 – abstract submission". Subjects for presentation can include results, reviews or plans and may have already been presented elsewhere. Naturally, there are limited oral presentation slots and these will be allocated to achieve a balanced programme.

Exhibition & Sponsorship

An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.

Organising Committee
  • Nicola Chessum, SCI / The Institute of Cancer Research
  • David Leese, SCI / Concept Life Sciences Ltd
  • Jayshree Mistry, SCI / Modgraph Consultants
  • Manisha Naik, SCI / Lilly
  • Jamie Scott, SCI / AstraZeneca

Become an SCI Member to receive benefits and discounts

Join SCI